Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide

Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide

Blog Article

We report utvara hellkite price our clinical experience with rituximab in the treatment of 2 patients with idiopathic cutaneous angiitis who relapsed after treatment with high-dose corticosteroids and cyclophosphamide.A 39-year-old woman and a 51-year-old man presented with ulcerating maculopapular rash in both lower limbs which relapsed 6 months after treatment with a combination of high-dose corticosteroids and cyclophosphamide.After treatment with 2 g of rituximab, the first patient has still been in clinical remission for 32 months while the second has finished 28 months.Interestingly, CD19 which had dropped to 0.5% 8 months later in both patients.

Despite that, our patients are still in clinical remission.No significant side effects toyo proxes st iii 305/40r22 were noted during infusions and up to the period of follow-up.In conclusion, rituximab is a useful and safe agent in the treatment of idiopathic cutaneous angiitis refractory to conventional therapy.Clinical remission persists years after improvement of B-cell suppression.